Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$152.20
+0.9%
$148.11
$127.59
$187.35
$41.95B0.212.84 million shs557,045 shs
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$564.19
+1.0%
$554.89
$506.91
$769.98
$44.50B1.55576,730 shs390,795 shs
Insulet Corporation stock logo
PODD
Insulet
$161.33
+1.9%
$152.91
$138.79
$354.88
$11.17B1.111.24 million shs368,862 shs
ResMed Inc. stock logo
RMD
ResMed
$205.02
-1.6%
$200.62
$180.26
$293.81
$29.74B0.781.28 million shs663,740 shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
+0.11%-4.68%-0.89%-2.19%-14.10%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
+0.53%+0.14%-3.50%-0.78%+3.32%
Insulet Corporation stock logo
PODD
Insulet
+0.53%-3.76%-0.83%-19.62%-46.79%
ResMed Inc. stock logo
RMD
ResMed
+1.41%-0.35%+6.04%-8.90%-18.42%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$152.20
+0.9%
$148.11
$127.59
$187.35
$41.95B0.212.84 million shs557,045 shs
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$564.19
+1.0%
$554.89
$506.91
$769.98
$44.50B1.55576,730 shs390,795 shs
Insulet Corporation stock logo
PODD
Insulet
$161.33
+1.9%
$152.91
$138.79
$354.88
$11.17B1.111.24 million shs368,862 shs
ResMed Inc. stock logo
RMD
ResMed
$205.02
-1.6%
$200.62
$180.26
$293.81
$29.74B0.781.28 million shs663,740 shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
+0.11%-4.68%-0.89%-2.19%-14.10%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
+0.53%+0.14%-3.50%-0.78%+3.32%
Insulet Corporation stock logo
PODD
Insulet
+0.53%-3.76%-0.83%-19.62%-46.79%
ResMed Inc. stock logo
RMD
ResMed
+1.41%-0.35%+6.04%-8.90%-18.42%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
2.38
Hold$180.2918.48% Upside
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
2.64
Moderate Buy$751.0033.02% Upside
Insulet Corporation stock logo
PODD
Insulet
2.71
Moderate Buy$237.0847.74% Upside
ResMed Inc. stock logo
RMD
ResMed
2.69
Moderate Buy$266.5530.27% Upside

Current Analyst Ratings Breakdown

Latest PODD, IDXX, BDX, and RMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2026
Insulet Corporation stock logo
PODD
Insulet
Lower Price TargetBuy$250.00 ➝ $225.00
7/8/2026
ResMed Inc. stock logo
RMD
ResMed
Lower Price TargetOutperform$321.00 ➝ $276.00
7/8/2026
Insulet Corporation stock logo
PODD
Insulet
Boost Price TargetNeutral$165.00 ➝ $172.00
7/8/2026
ResMed Inc. stock logo
RMD
ResMed
Lower Price TargetEqual Weight$227.00 ➝ $225.00
7/6/2026
Insulet Corporation stock logo
PODD
Insulet
Set Price Target$180.00
7/6/2026
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Set Price Target$180.00
7/1/2026
ResMed Inc. stock logo
RMD
ResMed
Reiterated RatingBuy
6/25/2026
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
UpgradeHold (C)Hold (C+)
6/24/2026
Insulet Corporation stock logo
PODD
Insulet
DowngradeHold (C-)Sell (D+)
6/23/2026
Insulet Corporation stock logo
PODD
Insulet
Initiated CoverageBuy$190.00
6/22/2026
ResMed Inc. stock logo
RMD
ResMed
Lower Price TargetOverweight$290.00 ➝ $266.00
(Data available from 7/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$21.84B1.92$23.34 per share6.52$88.58 per share1.72
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$4.45B10.02$15.33 per share36.83$20.10 per share28.09
Insulet Corporation stock logo
PODD
Insulet
$2.71B4.10$6.44 per share24.90$21.54 per share7.45
ResMed Inc. stock logo
RMD
ResMed
$5.15B5.77$11.13 per share18.38$40.70 per share5.03
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$1.68B$3.9538.5411.2910.655.33%15.37%7.11%8/6/2026 (Estimated)
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$1.06B$13.5841.5334.163.0424.63%70.87%32.56%8/4/2026 (Confirmed)
Insulet Corporation stock logo
PODD
Insulet
$247.10M$4.3037.3219.981.1010.44%26.87%12.01%8/5/2026 (Confirmed)
ResMed Inc. stock logo
RMD
ResMed
$1.40B$10.3719.7416.911.2127.44%25.35%18.69%8/6/2026 (Estimated)

Latest PODD, IDXX, BDX, and RMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q3 2026
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$3.14N/AN/AN/A$4.89 billionN/A
8/6/2026Q4 2026
ResMed Inc. stock logo
RMD
ResMed
$2.90N/AN/AN/A$1.47 billionN/A
8/5/2026Q2 2026
Insulet Corporation stock logo
PODD
Insulet
$1.45N/AN/AN/A$787.82 millionN/A
8/4/2026Q2 2026
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$3.95N/AN/AN/A$1.20 billionN/A
5/7/2026Q2 2026
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$2.77$2.90+$0.13-$1.11$4.67 billion$4.71 billion
5/6/2026Q1 2026
Insulet Corporation stock logo
PODD
Insulet
$1.19$1.42+$0.23$1.30$729.89 million$761.70 million
5/5/2026Q1 2026
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$3.41$3.47+$0.06$3.47$1.12 billion$1.14 billion
4/30/2026Q3 2026
ResMed Inc. stock logo
RMD
ResMed
$2.79$2.86+$0.07$2.74$1.42 billion$1.43 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$4.202.76%+5.65%106.33%53 Years
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
N/AN/AN/AN/AN/A
Insulet Corporation stock logo
PODD
Insulet
N/AN/AN/AN/AN/A
ResMed Inc. stock logo
RMD
ResMed
$2.401.17%+6.33%23.14%13 Years

Latest PODD, IDXX, BDX, and RMD Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/28/2026
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
quarterly$1.052.76%6/9/20266/9/20266/30/2026
4/30/2026
ResMed Inc. stock logo
RMD
ResMed
quarterly$0.601.18%5/14/20265/14/20266/18/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.62
0.94
0.55
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.19
1.12
0.82
Insulet Corporation stock logo
PODD
Insulet
0.71
2.49
1.81
ResMed Inc. stock logo
RMD
ResMed
0.06
3.01
2.33

Institutional Ownership

CompanyInstitutional Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
86.97%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
87.84%
Insulet Corporation stock logo
PODD
Insulet
N/A
ResMed Inc. stock logo
RMD
ResMed
54.98%

Insider Ownership

CompanyInsider Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.40%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.79%
Insulet Corporation stock logo
PODD
Insulet
0.36%
ResMed Inc. stock logo
RMD
ResMed
0.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
72,000275.54 million274.44 millionOptionable
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
11,00078.88 million78.26 millionOptionable
Insulet Corporation stock logo
PODD
Insulet
5,40069.26 million69.02 millionOptionable
ResMed Inc. stock logo
RMD
ResMed
10,600145.06 million144.11 millionOptionable

Recent News About These Companies

ResMed's Q4 2026 Earnings: What to Expect
ResMed Analyst Backs Portfolio Reset
ResMed (NYSE:RMD) CEO Sells 4,991 Shares
ResMed sharpens core focus with US$490 million MatrixCare sale
ResMed's $490m MatrixCare sale: What it means
Resmed Announces Agreement to Sell MatrixCare Business

New MarketBeat Followers Over Time

Media Sentiment Over Time

Becton, Dickinson and Company stock logo

Becton, Dickinson and Company NYSE:BDX

$152.09 +1.24 (+0.82%)
As of 03:40 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

IDEXX Laboratories stock logo

IDEXX Laboratories NASDAQ:IDXX

$564.28 +5.68 (+1.02%)
As of 03:40 PM Eastern
This is a fair market value price provided by Massive. Learn more.

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Insulet stock logo

Insulet NASDAQ:PODD

$161.19 +2.90 (+1.83%)
As of 03:40 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

ResMed stock logo

ResMed NYSE:RMD

$204.93 -3.52 (-1.69%)
As of 03:40 PM Eastern
This is a fair market value price provided by Massive. Learn more.

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.